Share this article
LAS VEGAS, Feb. 9, 2021 /PRNewswire/ DelveInsight s
Marginal Zone Lymphoma (MZL) Market report provides a complete comprehension of the Marginal Zone Lymphoma, historical and forecasted epidemiology and the MZL market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Marginal Zone Lymphoma market report also proffers an analysis of recent MZL treatment practice/algorithm, market drivers, market barriers and unmet medical needs.
Some of the highlights of
In May 2019, the FDA approved
lenalidomide (Revlimid) in combination with a rituximab product for previously treated follicular lymphoma (FL) and previously-treated MZL. Moreover, in December 2019, the European Commission approved Revlimid (lenalidomide) combined with rituximab to treat adult patients with previously treated Marginal Zone Lymphoma. The drug is not being approved in Japan but is expected to get launched in the forecast period